Pulmonary Arterial Hypertension News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Phase 2 in Pulmonary Arterial Hypertension Fails to Meet Endpoints - Rare Disease Report



Rare Disease Report
 
Phase 2 in Pulmonary Arterial Hypertension Fails to Meet Endpoints 
Rare Disease Report
In January 2017, Eiger BioPharmaceuticals, Inc. initiated its Phase 2 Pulmonary Arterial Hypertension (PAH) treatment study, evaluating the effects of ubenimex. Today, the company announced that results from the Phase 2 LIBERTY study demonstrated no ...
Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet ... PR Newswire (press release)
Eiger BioPharmaceuticals Halts Clinical Development of Ubenimex for PAH Pulmonary Hypertension News
Eiger to abandon blood pressure drug after trial failure Reuters
Xconomy  -FierceBiotech  -Seeking Alpha  -Zacks Investment Research 
all 68 news articles » 


Global Cardiovascular Disease Drugs Market 2017-2023 - Expiries ... - Business Wire (press release)



Global Cardiovascular Disease Drugs Market 2017-2023 - Expiries ... 
Business Wire (press release)
Global Cardiovascular Disease Drugs Market to 2023 provides an introduction to cardiovascular disease (CVD), including disease symptoms, diagnosis, etiology, pathophysiology, comorbidities and complications, epidemiology, prognosis and treatment. CVD ...

and more » 


OpportunityAnalyzer: Pulmonary Arterial Hypertension - Opportunity Analysis and Forecasts to 2026 - PR Newswire (press release)



OpportunityAnalyzer: Pulmonary Arterial Hypertension - Opportunity Analysis and Forecasts to 2026 
PR Newswire (press release)
Pulmonary arterial hypertension (PAH) is a rare, fatal cardiopulmonary disease with an annual mortality rate of 15%. The disease is a subset (Group 1) within the World Health Organization's (WHO's) classification of the different types of pulmonary ...
EpiCast Report: Pulmonary Arterial Hypertension ? Epidemiology Forecast to 2026 satPRnews (press release)
Pulmonary Arterial Hypertension: Market Insights, Epidemiology and Market Forecast to 2027 MilTech

all 3 news articles » 


Pulmonary Arterial Hypertension (PAH) Market by Key Players, Product and Production Information analysis and ... - GEOPOLMonitor



GEOPOLMonitor
 
Pulmonary Arterial Hypertension (PAH) Market by Key Players, Product and Production Information analysis and ... 
GEOPOLMonitor
Pulmonary Arterial Hypertension (PAH) Market report based on delivery model, application, services, and geography. A detailed analysis of the key industry players has been done to provide insights into their business, products and services, and key ...

and more » 


Liquidia Initiates Phase 3 Clinical Trial of LIQ861 in Patients with ... - Business Wire (press release)



Liquidia Initiates Phase 3 Clinical Trial of LIQ861 in Patients with ... 
Business Wire (press release)
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company focused on improving the performance of medicine by precisely engineering drug particles, today announced the initiation of a ...

and more » 


Arena Pharmaceuticals: Significance Of This Quarter's Catalysts - Seeking Alpha



Arena Pharmaceuticals: Significance Of This Quarter's Catalysts 
Seeking Alpha
Reading between the lines: some unexpected key events that may come to fruition this quarter. Arena will grow to fair value once this quarter's events unfold. Arena Pharmaceuticals (ARNA) has had a tremendous run in the last few months. It broke ...

 


Tracleer Seen to Benefit People with PH Due to IPF, Early Trial Data Shows - Pulmonary Hypertension News



Pulmonary Hypertension News
 
Tracleer Seen to Benefit People with PH Due to IPF, Early Trial Data Shows 
Pulmonary Hypertension News
But, as the study noted, there are no approved therapies to treat ?patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF), particularly those with idiopathic honeycomb lung.? Previous studies have suggested that PAH ...

 


Lupus Patients with PAH Have Relatively Good Survival Rates ... - Lupus News Today



Lupus Patients with PAH Have Relatively Good Survival Rates ... 
Lupus News Today
A retrospective study shows that 83.9% of patients suffering from SLE and pulmonary arterial hypertension (PAH) survive at least five years after diagnosis.
Pulmonary Arterial Hypertension (PAH) Market Report 2025 for ... satPRnews (press release)
Pulmonary Arterial Hypertension Treatment Market Opportunity ... MilTech

all 7 news articles » 


Eiger shares plummet 40% after phase 2 trial failure - MarketWatch



Eiger shares plummet 40% after phase 2 trial failure 
MarketWatch
Eiger BioPharmaceuticals Inc. EIGR, -49.37% shares dropped more than 40% in premarket trade Tuesday after the company said its pulmonary arterial hypertension drug failed to meet a primary and secondary endpoint both overall and in key subgroups. The ...

 


Phase 1 Trial for Camurus' Long-acting CAM2043 Gets Underway - Pulmonary Hypertension News



Phase 1 Trial for Camurus' Long-acting CAM2043 Gets Underway 
Pulmonary Hypertension News
The first healthy participants have been injected with CAM2043 (treprostinil FluidCrystal Injection Depot) in a Phase 1 study assessing the treatment's safety, tolerability, and pharmacokinetics in both single and repeated doses, the Swedish ...